nodes	percent_of_prediction	percent_of_DWPC	metapath
Auranofin—psoriatic arthritis—ankylosing spondylitis	0.372	0.574	CtDrD
Auranofin—IKBKB—Sulfasalazine—ankylosing spondylitis	0.294	0.902	CbGbCtD
Auranofin—rheumatoid arthritis—ankylosing spondylitis	0.276	0.426	CtDrD
Auranofin—ALB—Prednisone—ankylosing spondylitis	0.0213	0.0652	CbGbCtD
Auranofin—ALB—Methotrexate—ankylosing spondylitis	0.0107	0.0327	CbGbCtD
Auranofin—PRDX5—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.0014	0.057	CbGpPWpGaD
Auranofin—IKBKB—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.00134	0.0547	CbGpPWpGaD
Auranofin—IKBKB—NOD1/2 Signaling Pathway—CARD9—ankylosing spondylitis	0.00126	0.051	CbGpPWpGaD
Auranofin—IKBKB—Interleukin-1 signaling—IL1R2—ankylosing spondylitis	0.00118	0.048	CbGpPWpGaD
Auranofin—IKBKB—NOD pathway—CARD9—ankylosing spondylitis	0.001	0.0408	CbGpPWpGaD
Auranofin—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CARD9—ankylosing spondylitis	0.000856	0.0348	CbGpPWpGaD
Auranofin—IKBKB—IL17 signaling pathway—IL17A—ankylosing spondylitis	0.000721	0.0293	CbGpPWpGaD
Auranofin—PRDX5—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000696	0.0283	CbGpPWpGaD
Auranofin—IKBKB—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.000636	0.0259	CbGpPWpGaD
Auranofin—PRDX5—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000634	0.0258	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.000612	0.0249	CbGpPWpGaD
Auranofin—IKBKB—TNF receptor signaling pathway —TNFRSF1B—ankylosing spondylitis	0.00059	0.024	CbGpPWpGaD
Auranofin—IKBKB—Interleukin-1 signaling—IL1RN—ankylosing spondylitis	0.000558	0.0227	CbGpPWpGaD
Auranofin—IKBKB—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.000533	0.0217	CbGpPWpGaD
Auranofin—IKBKB—IKK complex recruitment mediated by RIP1—TLR4—ankylosing spondylitis	0.000485	0.0197	CbGpPWpGaD
Auranofin—IKBKB—Endogenous TLR signaling—TLR4—ankylosing spondylitis	0.000485	0.0197	CbGpPWpGaD
Auranofin—IKBKB—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.000458	0.0186	CbGpPWpGaD
Auranofin—IKBKB—Interleukin-1 signaling—IL1A—ankylosing spondylitis	0.000402	0.0163	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000375	0.0152	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.000364	0.0148	CbGpPWpGaD
Auranofin—IKBKB—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.000353	0.0144	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.000342	0.0139	CbGpPWpGaD
Auranofin—IKBKB—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.000339	0.0138	CbGpPWpGaD
Auranofin—IKBKB—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.000338	0.0137	CbGpPWpGaD
Auranofin—IKBKB—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000325	0.0132	CbGpPWpGaD
Auranofin—IKBKB—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.000312	0.0127	CbGpPWpGaD
Auranofin—IKBKB—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.000307	0.0125	CbGpPWpGaD
Auranofin—IKBKB—TCR signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000281	0.0114	CbGpPWpGaD
Auranofin—IKBKB—p75(NTR)-mediated signaling—MMP3—ankylosing spondylitis	0.000275	0.0112	CbGpPWpGaD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000258	0.0105	CbGpPWpGaD
Auranofin—IKBKB—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.000252	0.0103	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.000249	0.0101	CbGpPWpGaD
Auranofin—IKBKB—Type II diabetes mellitus—TNF—ankylosing spondylitis	0.000245	0.00998	CbGpPWpGaD
Auranofin—IKBKB—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.000241	0.00981	CbGpPWpGaD
Auranofin—IKBKB—EBV LMP1 signaling—TNF—ankylosing spondylitis	0.000237	0.00963	CbGpPWpGaD
Auranofin—IKBKB—Canonical NF-kappaB pathway—TNF—ankylosing spondylitis	0.000237	0.00963	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000221	0.00899	CbGpPWpGaD
Auranofin—IKBKB—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.00021	0.00854	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000202	0.0082	CbGpPWpGaD
Auranofin—IKBKB—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.000182	0.00738	CbGpPWpGaD
Auranofin—IKBKB—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.000163	0.00661	CbGpPWpGaD
Auranofin—IKBKB—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.000156	0.00634	CbGpPWpGaD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000152	0.00619	CbGpPWpGaD
Auranofin—IKBKB—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	0.000146	0.00595	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.000146	0.00594	CbGpPWpGaD
Auranofin—IKBKB—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.00014	0.00571	CbGpPWpGaD
Auranofin—IKBKB—B Cell Activation—CD79A—ankylosing spondylitis	0.000138	0.00561	CbGpPWpGaD
Auranofin—IKBKB—TNF receptor signaling pathway —TNF—ankylosing spondylitis	0.000136	0.00553	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000136	0.00551	CbGpPWpGaD
Auranofin—IKBKB—Immune System—KIR3DL1—ankylosing spondylitis	0.000134	0.00545	CbGpPWpGaD
Auranofin—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.000132	0.00537	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000128	0.00518	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000127	0.00517	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CARD9—ankylosing spondylitis	0.000121	0.00492	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—CRP—ankylosing spondylitis	0.000119	0.00484	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000119	0.00483	CbGpPWpGaD
Auranofin—IKBKB—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000118	0.00479	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000118	0.00479	CbGpPWpGaD
Auranofin—IKBKB—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000118	0.00478	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000117	0.00476	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	9.45e-05	0.00384	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	8.47e-05	0.00344	CbGpPWpGaD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	8.4e-05	0.00342	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—TNF—ankylosing spondylitis	8.4e-05	0.00342	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL1R2—ankylosing spondylitis	8.13e-05	0.0033	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	8.01e-05	0.00326	CbGpPWpGaD
Auranofin—IKBKB—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	7.81e-05	0.00318	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ERAP1—ankylosing spondylitis	7.71e-05	0.00313	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—HLA-C—ankylosing spondylitis	7.6e-05	0.00309	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	7.43e-05	0.00302	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—HLA-C—ankylosing spondylitis	7.3e-05	0.00297	CbGpPWpGaD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	7.19e-05	0.00292	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CARD9—ankylosing spondylitis	7.05e-05	0.00287	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	6.62e-05	0.00269	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	5.62e-05	0.00228	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CD79A—ankylosing spondylitis	5.57e-05	0.00226	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—TNF—ankylosing spondylitis	5.39e-05	0.00219	CbGpPWpGaD
Auranofin—Interstitial pneumonia—Methotrexate—ankylosing spondylitis	4.89e-05	0.0307	CcSEcCtD
Auranofin—IKBKB—MAPK Signaling Pathway—TNF—ankylosing spondylitis	4.83e-05	0.00196	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CD40LG—ankylosing spondylitis	4.54e-05	0.00184	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—HLA-B—ankylosing spondylitis	4.49e-05	0.00183	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HLA-C—ankylosing spondylitis	4.43e-05	0.0018	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—HLA-B—ankylosing spondylitis	4.32e-05	0.00175	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	4.28e-05	0.00174	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—HLA-A—ankylosing spondylitis	4e-05	0.00163	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CRP—ankylosing spondylitis	3.97e-05	0.00161	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL1RN—ankylosing spondylitis	3.85e-05	0.00156	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—TLR4—ankylosing spondylitis	3.81e-05	0.00155	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD79A—ankylosing spondylitis	3.38e-05	0.00137	CbGpPWpGaD
Auranofin—Interstitial lung disease—Methotrexate—ankylosing spondylitis	3.34e-05	0.0209	CcSEcCtD
Auranofin—Gingivitis—Methotrexate—ankylosing spondylitis	3.01e-05	0.0189	CcSEcCtD
Auranofin—IKBKB—Immune System—IL1A—ankylosing spondylitis	2.77e-05	0.00113	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD40LG—ankylosing spondylitis	2.75e-05	0.00112	CbGpPWpGaD
Auranofin—Proteinuria—Methotrexate—ankylosing spondylitis	2.69e-05	0.0169	CcSEcCtD
Auranofin—IKBKB—Signaling Pathways—PTGER4—ankylosing spondylitis	2.66e-05	0.00108	CbGpPWpGaD
Auranofin—Protein urine present—Methotrexate—ankylosing spondylitis	2.65e-05	0.0166	CcSEcCtD
Auranofin—IKBKB—Immune System—HLA-B—ankylosing spondylitis	2.62e-05	0.00106	CbGpPWpGaD
Auranofin—Glossitis—Methotrexate—ankylosing spondylitis	2.56e-05	0.0161	CcSEcCtD
Auranofin—Hepatic enzyme increased—Methotrexate—ankylosing spondylitis	2.5e-05	0.0157	CcSEcCtD
Auranofin—ALB—Metabolism—B3GNT2—ankylosing spondylitis	2.45e-05	0.000996	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HLA-A—ankylosing spondylitis	2.43e-05	0.000986	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CRP—ankylosing spondylitis	2.31e-05	0.000941	CbGpPWpGaD
Auranofin—Melaena—Methotrexate—ankylosing spondylitis	2.31e-05	0.0145	CcSEcCtD
Auranofin—IKBKB—Immune System—TLR4—ankylosing spondylitis	2.22e-05	0.000902	CbGpPWpGaD
Auranofin—Aplastic anaemia—Methotrexate—ankylosing spondylitis	2.22e-05	0.0139	CcSEcCtD
Auranofin—Neuropathy peripheral—Prednisolone—ankylosing spondylitis	2.13e-05	0.0134	CcSEcCtD
Auranofin—Conjunctivitis—Prednisolone—ankylosing spondylitis	2.11e-05	0.0133	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Prednisone—ankylosing spondylitis	2.05e-05	0.0129	CcSEcCtD
Auranofin—Neuropathy peripheral—Triamcinolone—ankylosing spondylitis	1.96e-05	0.0123	CcSEcCtD
Auranofin—Neuropathy peripheral—Methylprednisolone—ankylosing spondylitis	1.96e-05	0.0123	CcSEcCtD
Auranofin—Conjunctivitis—Triamcinolone—ankylosing spondylitis	1.94e-05	0.0122	CcSEcCtD
Auranofin—IKBKB—Signaling Pathways—MMP3—ankylosing spondylitis	1.89e-05	0.000769	CbGpPWpGaD
Auranofin—Visual impairment—Prednisolone—ankylosing spondylitis	1.88e-05	0.0118	CcSEcCtD
Auranofin—Weight decreased—Betamethasone—ankylosing spondylitis	1.84e-05	0.0116	CcSEcCtD
Auranofin—Weight decreased—Dexamethasone—ankylosing spondylitis	1.84e-05	0.0116	CcSEcCtD
Auranofin—Dermatitis exfoliative—Methotrexate—ankylosing spondylitis	1.82e-05	0.0114	CcSEcCtD
Auranofin—Neuropathy peripheral—Dexamethasone—ankylosing spondylitis	1.78e-05	0.0112	CcSEcCtD
Auranofin—Neuropathy peripheral—Betamethasone—ankylosing spondylitis	1.78e-05	0.0112	CcSEcCtD
Auranofin—Conjunctivitis—Betamethasone—ankylosing spondylitis	1.76e-05	0.0111	CcSEcCtD
Auranofin—Conjunctivitis—Dexamethasone—ankylosing spondylitis	1.76e-05	0.0111	CcSEcCtD
Auranofin—Visual impairment—Methylprednisolone—ankylosing spondylitis	1.73e-05	0.0108	CcSEcCtD
Auranofin—Eye disorder—Methylprednisolone—ankylosing spondylitis	1.67e-05	0.0105	CcSEcCtD
Auranofin—Neutropenia—Prednisone—ankylosing spondylitis	1.66e-05	0.0104	CcSEcCtD
Auranofin—Weight decreased—Prednisone—ankylosing spondylitis	1.6e-05	0.0101	CcSEcCtD
Auranofin—Visual impairment—Dexamethasone—ankylosing spondylitis	1.57e-05	0.00985	CcSEcCtD
Auranofin—Visual impairment—Betamethasone—ankylosing spondylitis	1.57e-05	0.00985	CcSEcCtD
Auranofin—Angioedema—Prednisolone—ankylosing spondylitis	1.55e-05	0.00975	CcSEcCtD
Auranofin—Neuropathy peripheral—Prednisone—ankylosing spondylitis	1.55e-05	0.00972	CcSEcCtD
Auranofin—Dysgeusia—Triamcinolone—ankylosing spondylitis	1.53e-05	0.00961	CcSEcCtD
Auranofin—Eye disorder—Betamethasone—ankylosing spondylitis	1.52e-05	0.00955	CcSEcCtD
Auranofin—Eye disorder—Dexamethasone—ankylosing spondylitis	1.52e-05	0.00955	CcSEcCtD
Auranofin—Eosinophilia—Methotrexate—ankylosing spondylitis	1.47e-05	0.0092	CcSEcCtD
Auranofin—Alopecia—Dexamethasone—ankylosing spondylitis	1.44e-05	0.00903	CcSEcCtD
Auranofin—Alopecia—Betamethasone—ankylosing spondylitis	1.44e-05	0.00903	CcSEcCtD
Auranofin—Angioedema—Triamcinolone—ankylosing spondylitis	1.43e-05	0.00896	CcSEcCtD
Auranofin—Angioedema—Methylprednisolone—ankylosing spondylitis	1.42e-05	0.00894	CcSEcCtD
Auranofin—Pancytopenia—Methotrexate—ankylosing spondylitis	1.41e-05	0.00883	CcSEcCtD
Auranofin—Neutropenia—Methotrexate—ankylosing spondylitis	1.39e-05	0.00869	CcSEcCtD
Auranofin—Eye disorder—Prednisone—ankylosing spondylitis	1.33e-05	0.00832	CcSEcCtD
Auranofin—Angioedema—Dexamethasone—ankylosing spondylitis	1.3e-05	0.00813	CcSEcCtD
Auranofin—Angioedema—Betamethasone—ankylosing spondylitis	1.3e-05	0.00813	CcSEcCtD
Auranofin—Stomatitis—Methotrexate—ankylosing spondylitis	1.29e-05	0.00808	CcSEcCtD
Auranofin—Conjunctivitis—Methotrexate—ankylosing spondylitis	1.28e-05	0.00806	CcSEcCtD
Auranofin—Haematuria—Methotrexate—ankylosing spondylitis	1.26e-05	0.0079	CcSEcCtD
Auranofin—Alopecia—Prednisone—ankylosing spondylitis	1.25e-05	0.00787	CcSEcCtD
Auranofin—Agranulocytosis—Methotrexate—ankylosing spondylitis	1.23e-05	0.00774	CcSEcCtD
Auranofin—Visual impairment—Methotrexate—ankylosing spondylitis	1.14e-05	0.00717	CcSEcCtD
Auranofin—Anaemia—Prednisone—ankylosing spondylitis	1.14e-05	0.00716	CcSEcCtD
Auranofin—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	1.13e-05	0.00711	CcSEcCtD
Auranofin—Thrombocytopenia—Betamethasone—ankylosing spondylitis	1.13e-05	0.00711	CcSEcCtD
Auranofin—Angioedema—Prednisone—ankylosing spondylitis	1.13e-05	0.00708	CcSEcCtD
Auranofin—Dyspepsia—Triamcinolone—ankylosing spondylitis	1.12e-05	0.00705	CcSEcCtD
Auranofin—Dyspepsia—Methylprednisolone—ankylosing spondylitis	1.12e-05	0.00703	CcSEcCtD
Auranofin—Eye disorder—Methotrexate—ankylosing spondylitis	1.11e-05	0.00695	CcSEcCtD
Auranofin—Anorexia—Dexamethasone—ankylosing spondylitis	1.1e-05	0.00692	CcSEcCtD
Auranofin—Anorexia—Betamethasone—ankylosing spondylitis	1.1e-05	0.00692	CcSEcCtD
Auranofin—Urticaria—Prednisolone—ankylosing spondylitis	1.1e-05	0.00692	CcSEcCtD
Auranofin—Alopecia—Methotrexate—ankylosing spondylitis	1.05e-05	0.00658	CcSEcCtD
Auranofin—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	1.04e-05	0.00653	CcSEcCtD
Auranofin—Dyspepsia—Betamethasone—ankylosing spondylitis	1.02e-05	0.00639	CcSEcCtD
Auranofin—Dyspepsia—Dexamethasone—ankylosing spondylitis	1.02e-05	0.00639	CcSEcCtD
Auranofin—Urticaria—Triamcinolone—ankylosing spondylitis	1.01e-05	0.00636	CcSEcCtD
Auranofin—Urticaria—Methylprednisolone—ankylosing spondylitis	1.01e-05	0.00635	CcSEcCtD
Auranofin—Dysgeusia—Methotrexate—ankylosing spondylitis	1.01e-05	0.00634	CcSEcCtD
Auranofin—Abdominal pain—Methylprednisolone—ankylosing spondylitis	1.01e-05	0.00631	CcSEcCtD
Auranofin—Decreased appetite—Betamethasone—ankylosing spondylitis	1.01e-05	0.00631	CcSEcCtD
Auranofin—Decreased appetite—Dexamethasone—ankylosing spondylitis	1.01e-05	0.00631	CcSEcCtD
Auranofin—Anorexia—Prednisone—ankylosing spondylitis	9.61e-06	0.00603	CcSEcCtD
Auranofin—Anaemia—Methotrexate—ankylosing spondylitis	9.54e-06	0.00599	CcSEcCtD
Auranofin—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	9.46e-06	0.00594	CcSEcCtD
Auranofin—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	9.46e-06	0.00594	CcSEcCtD
Auranofin—Leukopenia—Methotrexate—ankylosing spondylitis	9.24e-06	0.0058	CcSEcCtD
Auranofin—Urticaria—Betamethasone—ankylosing spondylitis	9.19e-06	0.00577	CcSEcCtD
Auranofin—Urticaria—Dexamethasone—ankylosing spondylitis	9.19e-06	0.00577	CcSEcCtD
Auranofin—Abdominal pain—Dexamethasone—ankylosing spondylitis	9.15e-06	0.00574	CcSEcCtD
Auranofin—Abdominal pain—Betamethasone—ankylosing spondylitis	9.15e-06	0.00574	CcSEcCtD
Auranofin—Pruritus—Triamcinolone—ankylosing spondylitis	9.02e-06	0.00566	CcSEcCtD
Auranofin—Pruritus—Methylprednisolone—ankylosing spondylitis	9e-06	0.00565	CcSEcCtD
Auranofin—Dyspepsia—Prednisone—ankylosing spondylitis	8.87e-06	0.00557	CcSEcCtD
Auranofin—Decreased appetite—Prednisone—ankylosing spondylitis	8.76e-06	0.0055	CcSEcCtD
Auranofin—Rash—Prednisolone—ankylosing spondylitis	8.75e-06	0.00549	CcSEcCtD
Auranofin—Dermatitis—Prednisolone—ankylosing spondylitis	8.74e-06	0.00548	CcSEcCtD
Auranofin—Diarrhoea—Methylprednisolone—ankylosing spondylitis	8.71e-06	0.00546	CcSEcCtD
Auranofin—Constipation—Prednisone—ankylosing spondylitis	8.62e-06	0.00541	CcSEcCtD
Auranofin—Thrombocytopenia—Methotrexate—ankylosing spondylitis	8.25e-06	0.00518	CcSEcCtD
Auranofin—Gastrointestinal pain—Prednisone—ankylosing spondylitis	8.24e-06	0.00517	CcSEcCtD
Auranofin—Nausea—Prednisolone—ankylosing spondylitis	8.24e-06	0.00517	CcSEcCtD
Auranofin—Pruritus—Betamethasone—ankylosing spondylitis	8.19e-06	0.00514	CcSEcCtD
Auranofin—Pruritus—Dexamethasone—ankylosing spondylitis	8.19e-06	0.00514	CcSEcCtD
Auranofin—Vomiting—Triamcinolone—ankylosing spondylitis	8.11e-06	0.00509	CcSEcCtD
Auranofin—Vomiting—Methylprednisolone—ankylosing spondylitis	8.09e-06	0.00508	CcSEcCtD
Auranofin—Rash—Triamcinolone—ankylosing spondylitis	8.04e-06	0.00505	CcSEcCtD
Auranofin—Dermatitis—Triamcinolone—ankylosing spondylitis	8.04e-06	0.00504	CcSEcCtD
Auranofin—Anorexia—Methotrexate—ankylosing spondylitis	8.03e-06	0.00504	CcSEcCtD
Auranofin—Rash—Methylprednisolone—ankylosing spondylitis	8.02e-06	0.00504	CcSEcCtD
Auranofin—Dermatitis—Methylprednisolone—ankylosing spondylitis	8.02e-06	0.00503	CcSEcCtD
Auranofin—Urticaria—Prednisone—ankylosing spondylitis	8.01e-06	0.00503	CcSEcCtD
Auranofin—Abdominal pain—Prednisone—ankylosing spondylitis	7.97e-06	0.005	CcSEcCtD
Auranofin—Diarrhoea—Dexamethasone—ankylosing spondylitis	7.92e-06	0.00497	CcSEcCtD
Auranofin—Diarrhoea—Betamethasone—ankylosing spondylitis	7.92e-06	0.00497	CcSEcCtD
Auranofin—Nausea—Triamcinolone—ankylosing spondylitis	7.58e-06	0.00475	CcSEcCtD
Auranofin—Nausea—Methylprednisolone—ankylosing spondylitis	7.56e-06	0.00474	CcSEcCtD
Auranofin—Dyspepsia—Methotrexate—ankylosing spondylitis	7.42e-06	0.00465	CcSEcCtD
Auranofin—Vomiting—Betamethasone—ankylosing spondylitis	7.36e-06	0.00462	CcSEcCtD
Auranofin—Vomiting—Dexamethasone—ankylosing spondylitis	7.36e-06	0.00462	CcSEcCtD
Auranofin—Decreased appetite—Methotrexate—ankylosing spondylitis	7.32e-06	0.0046	CcSEcCtD
Auranofin—Rash—Betamethasone—ankylosing spondylitis	7.3e-06	0.00458	CcSEcCtD
Auranofin—Rash—Dexamethasone—ankylosing spondylitis	7.3e-06	0.00458	CcSEcCtD
Auranofin—Dermatitis—Betamethasone—ankylosing spondylitis	7.29e-06	0.00458	CcSEcCtD
Auranofin—Dermatitis—Dexamethasone—ankylosing spondylitis	7.29e-06	0.00458	CcSEcCtD
Auranofin—Pruritus—Prednisone—ankylosing spondylitis	7.13e-06	0.00448	CcSEcCtD
Auranofin—Diarrhoea—Prednisone—ankylosing spondylitis	6.9e-06	0.00433	CcSEcCtD
Auranofin—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	6.89e-06	0.00432	CcSEcCtD
Auranofin—Nausea—Dexamethasone—ankylosing spondylitis	6.87e-06	0.00431	CcSEcCtD
Auranofin—Nausea—Betamethasone—ankylosing spondylitis	6.87e-06	0.00431	CcSEcCtD
Auranofin—Urticaria—Methotrexate—ankylosing spondylitis	6.69e-06	0.0042	CcSEcCtD
Auranofin—Abdominal pain—Methotrexate—ankylosing spondylitis	6.66e-06	0.00418	CcSEcCtD
Auranofin—Vomiting—Prednisone—ankylosing spondylitis	6.41e-06	0.00402	CcSEcCtD
Auranofin—Rash—Prednisone—ankylosing spondylitis	6.36e-06	0.00399	CcSEcCtD
Auranofin—Dermatitis—Prednisone—ankylosing spondylitis	6.35e-06	0.00398	CcSEcCtD
Auranofin—Nausea—Prednisone—ankylosing spondylitis	5.99e-06	0.00376	CcSEcCtD
Auranofin—Pruritus—Methotrexate—ankylosing spondylitis	5.96e-06	0.00374	CcSEcCtD
Auranofin—Diarrhoea—Methotrexate—ankylosing spondylitis	5.76e-06	0.00362	CcSEcCtD
Auranofin—Vomiting—Methotrexate—ankylosing spondylitis	5.36e-06	0.00336	CcSEcCtD
Auranofin—Rash—Methotrexate—ankylosing spondylitis	5.31e-06	0.00333	CcSEcCtD
Auranofin—Dermatitis—Methotrexate—ankylosing spondylitis	5.31e-06	0.00333	CcSEcCtD
Auranofin—Nausea—Methotrexate—ankylosing spondylitis	5e-06	0.00314	CcSEcCtD
